首页> 外国专利> Biocompatible microparticles of Alginic acid composition for controlled release of active principles intravenously

Biocompatible microparticles of Alginic acid composition for controlled release of active principles intravenously

机译:海藻酸组合物的生物相容性微粒,用于静脉内控制释放活性成分

摘要

Components of alginate bioactive particles for controlled release of active substances by intravenous injection. The present application relates to bioavailable ingredients, including seaweed particles or their salts and active ingredients. More specifically, the present application relates to the microparticles to be injected into the active original package of the patients in need. These particles have a combination of appropriate sizes to ensure an increase in average life or durability of the active blood principle,In the case of intravenous injection, the absorption rate of liver is low and the cells are clarified rapidly. 1. Characteristic 1: bioavailable components in intravenous injection, including seaweed particles or their salts used to control the release of active components, which are characterized by their volume less than or equal to 5 microns and have negative Z potential. Requirement 3: composition. According to requirement 1, the potential of Z is between - 70 and 0, excluding 0. Claim 19: the procedure described in claim 18,It is characterized by the fact that the principle of activity can be human, animal, recombinant or transgenic. 19. Claim 21: the procedure described in claim 18, characterized in that the principle of activity is a factor in blood clotting. Claim 27: in the treatment of haemorrhagic disorders, coagulation disorders and hormonal diseases, biological adaptive ingredients are used in accordance with any one of claims 1 to 12.
机译:海藻酸盐生物活性颗粒的成分,用于通过静脉内注射控制活性物质的释放。本申请涉及生物可利用成分,包括海藻颗粒或其盐和活性成分。更具体地,本申请涉及将被注射到需要的患者的活性原始包装中的微粒。这些颗粒具有适当大小的组合,以确保增加活性血原理的平均寿命或持久性。在静脉内注射的情况下,肝脏的吸收率低,细胞迅速澄清。 1.特征1:静脉注射中的生物可利用成分,包括用于控制活性成分释放的海藻颗粒或其盐,其特征在于其体积小于或等于5微米且Z值为负。要求3:组成。根据要求1,Z的电势在-70至0之间,不包括0。权利要求19:权利要求18所述的方法,其特征在于活性原理可以是人,动物,重组或转基因的。 19.权利要求21:根据权利要求18所述的方法,其特征在于,所述活动原理是血液凝固的因素。权利要求27:在治疗出血性疾病,凝血障碍和激素疾病中,根据权利要求1至12中任一项使用生物适应性成分。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号